According to results from the phase 3b TOGETHER-PsO trial, the use of concomitant ixekizumab and tirzepatide improved skin clearance and reduced weight among patients with moderate to severe psoriasis and overweight or obesity. The trial was presented at the 2026 American Academy of Dermatology Annual Meeting.
The study enrolled adults with moderate to severe plaque psoriasis and a body mass index of 27 or higher. Patients received ixekizumab (a biologic targeting IL-17A) plus tirzepatide (a GIP/GLP-1 receptor agonist) or ixekizumab alone. At week 24, 72% of patients in the combination group achieved at least 90% improvement in the Psoriasis Area and Severity Index (PASI 90), compared to 48% in the monotherapy group.
Additionally, patients in the combination group lost an average of 12.5% of their body weight, while those on ixekizumab alone lost 1.1%. The combination was generally well-tolerated, with gastrointestinal side effects being the most common adverse events, consistent with known tirzepatide safety profile.
These findings suggest that combining a biologic with a weight-loss medication may address both skin and metabolic comorbidities in psoriasis patients. Further research is needed to assess long-term outcomes and broader applicability.
